Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 6, 2006, Pages 702-706

  Pedraz, Javier ^a   Dauden E ^a   Delgado Jimenez Y ^a   Garcia Rio I ^a   Garcia Diez A ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Cyclosporin; Mycophenolate mofetil; Psoriasis

Indexed keywords

ANTIPSORIASIS AGENT; CREATININE; CYCLOSPORIN A; ETRETIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EPIDEMIC; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPERTRICHOSIS; INSOMNIA; MALE; OPEN STUDY; POLYURIA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS VULGARIS; QUANTITATIVE ANALYSIS; REMISSION; SEQUENTIAL ANALYSIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CHRONIC DISEASE; CROSS-OVER STUDIES; CYCLOSPORINE; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; PSORIASIS;

EID: 33745259014     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01577.x     Document Type: Article

References (16)

1. Lebwohl M, Ali S. Treatment of psoriasis. 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-498.
2. Lebwohl M, Ali S. Treatment of psoriasis. 2. Systemic therapies. J Am Acad Dermatol 2001; 45: 649-661.
3. Geilen CC, Tebbe B, García-Bartels C, Krengel S, Orfanos CE. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol 1998; 138: 1101-1102.
4. Haufs MG, Beissert S, Grabbe S, Schutte B, Luger TA. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 1998; 138: 179-181.
5. Tong DW, Walder BK. Widespread plaque psoriasis responsive to mycophenolate mofetil. Australas J Dermatol 1999; 40: 135-137.
6. Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999; 40: 265-268.
7. Grundmann-Kollmann M, Mooser G, Schraeder P et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mophetil. J Am Acad Dermatol 2000; 42: 835-837.
8. Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: Positive experience in 11 patients. Br J Dermatol 2001; 144: 583-586.
9. Dauden E, Sánchez-Peinado C, Ruiz-Genao D et al. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. Br J Dermatol 2004; 150: 132-135.
10. Griffiths CEM, Powles AV, McFadden J et al. Long-term cyclosporin for psoriasis. Br J Dermatol 1989; 120: 253-260.
11. Berth-Jones J, Henderson CA, Munro CS et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral): A multicenter study. Br J Dermatol 1997; 136: 527-530.
12. Spuls PI, Witkamp L, Bossuyt PMM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943-949.
13. Ho VC, Griffiths CEM, Albrecht G et al. Intermittent short courses of cyclosporin (Neoral) for psoriasis unresponsive to topical therapy: A 1-year multicentre, randomised study. Br J Dermatol 1999; 141: 283-291.
14. Ho VC, Griffiths CEM, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. J Am Acad Dermatol 2001; 44: 643-651.
15. Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporine to mycophenolate mofetil in severe psoriasis. Br J Dermatol 2000; 143: 405-407.
16. Griffiths CEM, Dubertret L, Ellis CN et al. Ciclosporin in psoriasis clinical practice: An international consensus statement. Br J Dermatol 2004; 150 (Suppl. 67): 11-23.